|
Brussels, |
|
EU Competition Policy
Pharmaceuticals and Health Services
European citizens and healthcare systems depend on timely access to safe, innovative and affordable medicines, medical devices and health services. Effective competition encourages companies to compete on price, quality, research and innovation, while helping public authorities make sustainable use of healthcare budgets.
EU competition policy applies throughout the healthcare value chain, from pharmaceutical research and manufacturing to distribution, medical technologies, pharmacies, hospitals and other health-related services.
The role of competition policy
Competition policy helps preserve market conditions in which innovative treatments can be developed and competing products can reach patients without unjustified delay.
The European Commission and national competition authorities may intervene through:
Pharmaceutical research and innovation
Developing a new medicine is generally a lengthy, costly and uncertain process. Pharmaceutical companies may invest for many years in laboratory research, clinical trials, regulatory approval and manufacturing before a product reaches the market.
Patents and other forms of regulatory protection are therefore important incentives for innovation. They allow companies to recover research and development costs and finance future treatments.
However, certain strategies intended to protect exclusivity may raise competition concerns when they delay the market entry of competing products without sufficient justification.
These practices may include:
The Commission specifically identifies patent clusters, patent thickets and certain patent settlements among the practices that may, depending on the circumstances, infringe EU competition law.
Generic and biosimilar medicines
Generic and biosimilar medicines play an important role in pharmaceutical competition. Their entry can provide patients with additional treatment options and generate significant savings for national healthcare systems.
Competition policy may intervene where an originator company takes unlawful steps to delay or prevent entry by generic or biosimilar competitors.
Potential concerns include:
Effective generic and biosimilar competition can reduce expenditure while allowing healthcare systems to redirect resources towards new and innovative treatments.
Patent settlements and pay-for-delay agreements
Disputes between originator companies and generic manufacturers are common because market entry may depend on the validity or scope of pharmaceutical patents.
Parties are generally free to settle genuine patent disputes. However, competition concerns may arise where a settlement includes a transfer of value to a potential competitor in exchange for delayed or restricted market entry.
Such arrangements are often described as pay-for-delay agreements.
The assessment considers the substance of the agreement, the relationship between the parties, the restrictions imposed and whether the arrangement reduces potential competition beyond the legitimate scope of the patent.
Pricing, reimbursement and affordability
Prices and reimbursement conditions for medicines are largely determined by national authorities. Nevertheless, competition between pharmaceutical companies can influence the prices paid by healthcare systems, insurers and patients.
Competition concerns may arise where companies:
Competition enforcement cannot by itself resolve every issue concerning pharmaceutical affordability. It can, however, address conduct that artificially reduces competition or prevents healthcare purchasers from obtaining better terms.
Pharmaceutical distribution and supply chains
Medicines reach patients through a regulated supply chain involving manufacturers, importers, wholesalers, logistics providers, pharmacies, hospitals and online distributors.
Competition policy may apply to:
Restrictions may be justified in some circumstances by patient safety, product integrity or continuity-of-supply requirements. They must, however, remain necessary and proportionate.
Medical devices and health technologies
Competition rules also apply to medical devices, diagnostic products, digital-health technologies, laboratory equipment and other health-related products.
Relevant markets may include:
Competition concerns can arise where a supplier controls proprietary data, technical interfaces, consumables, software updates or maintenance services needed for the continued use of medical equipment.
Interoperability and access to data are becoming increasingly important as healthcare systems become more digital and connected.
Hospitals and health services
EU competition rules can apply to healthcare providers when they carry out economic activities by offering goods or services on a market.
This may include:
The application of competition and State aid rules depends on how a national healthcare system is organised, financed and regulated.
Services based on solidarity and provided as part of a non-economic public system may fall outside competition rules. Commercial healthcare activities may, by contrast, be subject to them.
Mergers and acquisitions
The pharmaceutical and healthcare industries have experienced substantial consolidation through mergers, acquisitions, licensing transactions and purchases of biotechnology companies.
The European Commission reviews transactions that could significantly reduce effective competition.
Its assessment may examine:
A merger can raise concerns even before competing products reach the market when it removes a credible research programme or an important source of future innovation.
The Commission may approve a transaction, prohibit it or require remedies such as the divestiture of products, research programmes, licences or production assets.
Competition in pharmaceutical innovation
Assessing competition in pharmaceuticals often requires looking beyond products already available to patients.
Authorities may examine competition between:
This approach is intended to prevent mergers or exclusionary practices from reducing innovation before their effects become visible in existing product markets.
The Commission’s updated report on pharmaceutical competition enforcement explains how antitrust and merger decisions by the Commission and national authorities have contributed to access to affordable and innovative medicines.
State aid and public support
Public authorities may support healthcare infrastructure, pharmaceutical research, vaccine development, medical manufacturing and access to essential services.
EU State aid rules seek to ensure that support:
Public support may concern:
The compatibility assessment depends on the nature of the beneficiary, the activity financed and the design of the measure.
Public procurement in healthcare
Hospitals, health ministries and other public bodies are major purchasers of medicines, devices and healthcare services.
Competitive procurement can improve value for money, encourage innovation and reduce the risk of dependency on a limited number of suppliers.
Competition concerns may involve:
Businesses participating in healthcare procurement must comply with both competition law and public-procurement rules.
EU competition policy applies throughout the healthcare value chain, from pharmaceutical research and manufacturing to distribution, medical technologies, pharmacies, hospitals and other health-related services.
The role of competition policy
Competition policy helps preserve market conditions in which innovative treatments can be developed and competing products can reach patients without unjustified delay.
The European Commission and national competition authorities may intervene through:
- antitrust and cartel enforcement;
- investigations into abuses of dominant positions;
- merger control;
- State aid supervision;
- scrutiny of agreements affecting market entry;
- action against practices that restrict access to medicines or healthcare markets.
Pharmaceutical research and innovation
Developing a new medicine is generally a lengthy, costly and uncertain process. Pharmaceutical companies may invest for many years in laboratory research, clinical trials, regulatory approval and manufacturing before a product reaches the market.
Patents and other forms of regulatory protection are therefore important incentives for innovation. They allow companies to recover research and development costs and finance future treatments.
However, certain strategies intended to protect exclusivity may raise competition concerns when they delay the market entry of competing products without sufficient justification.
These practices may include:
- overlapping portfolios of patents;
- complex patent structures or “patent thickets”;
- defensive patent filings;
- litigation strategies intended primarily to delay competitors;
- agreements between originator and generic companies;
- acquisitions that remove emerging competitive threats.
The Commission specifically identifies patent clusters, patent thickets and certain patent settlements among the practices that may, depending on the circumstances, infringe EU competition law.
Generic and biosimilar medicines
Generic and biosimilar medicines play an important role in pharmaceutical competition. Their entry can provide patients with additional treatment options and generate significant savings for national healthcare systems.
Competition policy may intervene where an originator company takes unlawful steps to delay or prevent entry by generic or biosimilar competitors.
Potential concerns include:
- agreements under which a competitor accepts delayed market entry;
- misuse of patent or regulatory procedures;
- misleading representations to public authorities;
- exclusionary pricing practices;
- restrictions on access to samples or information needed for approval;
- commercial arrangements that foreclose competing products.
Effective generic and biosimilar competition can reduce expenditure while allowing healthcare systems to redirect resources towards new and innovative treatments.
Patent settlements and pay-for-delay agreements
Disputes between originator companies and generic manufacturers are common because market entry may depend on the validity or scope of pharmaceutical patents.
Parties are generally free to settle genuine patent disputes. However, competition concerns may arise where a settlement includes a transfer of value to a potential competitor in exchange for delayed or restricted market entry.
Such arrangements are often described as pay-for-delay agreements.
The assessment considers the substance of the agreement, the relationship between the parties, the restrictions imposed and whether the arrangement reduces potential competition beyond the legitimate scope of the patent.
Pricing, reimbursement and affordability
Prices and reimbursement conditions for medicines are largely determined by national authorities. Nevertheless, competition between pharmaceutical companies can influence the prices paid by healthcare systems, insurers and patients.
Competition concerns may arise where companies:
- coordinate prices or commercial conditions;
- divide customers or geographic markets;
- restrict parallel trade;
- impose exclusionary rebate systems;
- charge unfair prices while holding a dominant position;
- manipulate procurement or tender procedures;
- prevent lower-priced competing products from entering the market.
Competition enforcement cannot by itself resolve every issue concerning pharmaceutical affordability. It can, however, address conduct that artificially reduces competition or prevents healthcare purchasers from obtaining better terms.
Pharmaceutical distribution and supply chains
Medicines reach patients through a regulated supply chain involving manufacturers, importers, wholesalers, logistics providers, pharmacies, hospitals and online distributors.
Competition policy may apply to:
- distribution agreements;
- wholesale access and supply conditions;
- allocation and shortage-management practices;
- pharmacy networks;
- online sales restrictions;
- parallel distribution;
- procurement by hospitals and health authorities;
- access to essential products and infrastructure.
Restrictions may be justified in some circumstances by patient safety, product integrity or continuity-of-supply requirements. They must, however, remain necessary and proportionate.
Medical devices and health technologies
Competition rules also apply to medical devices, diagnostic products, digital-health technologies, laboratory equipment and other health-related products.
Relevant markets may include:
- diagnostic imaging;
- laboratory and testing systems;
- implants and surgical products;
- hospital equipment;
- in-vitro diagnostics;
- monitoring devices;
- digital-health platforms;
- healthcare software;
- artificial-intelligence applications;
- maintenance and after-sales services.
Competition concerns can arise where a supplier controls proprietary data, technical interfaces, consumables, software updates or maintenance services needed for the continued use of medical equipment.
Interoperability and access to data are becoming increasingly important as healthcare systems become more digital and connected.
Hospitals and health services
EU competition rules can apply to healthcare providers when they carry out economic activities by offering goods or services on a market.
This may include:
- private hospitals and clinics;
- diagnostic laboratories;
- rehabilitation services;
- pharmacies;
- healthcare-management companies;
- home-care providers;
- digital-health services;
- outsourced hospital functions.
The application of competition and State aid rules depends on how a national healthcare system is organised, financed and regulated.
Services based on solidarity and provided as part of a non-economic public system may fall outside competition rules. Commercial healthcare activities may, by contrast, be subject to them.
Mergers and acquisitions
The pharmaceutical and healthcare industries have experienced substantial consolidation through mergers, acquisitions, licensing transactions and purchases of biotechnology companies.
The European Commission reviews transactions that could significantly reduce effective competition.
Its assessment may examine:
- overlaps between existing medicines;
- competition between products in development;
- research pipelines;
- innovation capabilities;
- therapeutic areas;
- access to patents, data and technology;
- medical-device and diagnostic markets;
- distribution and healthcare-service networks.
A merger can raise concerns even before competing products reach the market when it removes a credible research programme or an important source of future innovation.
The Commission may approve a transaction, prohibit it or require remedies such as the divestiture of products, research programmes, licences or production assets.
Competition in pharmaceutical innovation
Assessing competition in pharmaceuticals often requires looking beyond products already available to patients.
Authorities may examine competition between:
- research programmes targeting the same disease;
- alternative treatment mechanisms;
- medicines at different stages of clinical development;
- companies with specialised scientific capabilities;
- platforms capable of developing future therapies.
This approach is intended to prevent mergers or exclusionary practices from reducing innovation before their effects become visible in existing product markets.
The Commission’s updated report on pharmaceutical competition enforcement explains how antitrust and merger decisions by the Commission and national authorities have contributed to access to affordable and innovative medicines.
State aid and public support
Public authorities may support healthcare infrastructure, pharmaceutical research, vaccine development, medical manufacturing and access to essential services.
EU State aid rules seek to ensure that support:
- pursues a genuine public-interest objective;
- is necessary and proportionate;
- avoids unnecessary advantages for selected operators;
- preserves competition where markets exist;
- does not crowd out private investment without justification.
Public support may concern:
- research and development;
- manufacturing capacity;
- hospitals and health infrastructure;
- emergency preparedness;
- vaccines and essential medicines;
- digital-health systems;
- regional healthcare access;
- services of general economic interest.
The compatibility assessment depends on the nature of the beneficiary, the activity financed and the design of the measure.
Public procurement in healthcare
Hospitals, health ministries and other public bodies are major purchasers of medicines, devices and healthcare services.
Competitive procurement can improve value for money, encourage innovation and reduce the risk of dependency on a limited number of suppliers.
Competition concerns may involve:
- bid rigging;
- information exchange between bidders;
- market allocation;
- discriminatory tender conditions;
- procurement specifications favouring a particular supplier;
- long-term exclusivity that prevents market entry;
- bundling of products and maintenance services.
Businesses participating in healthcare procurement must comply with both competition law and public-procurement rules.
Pharmaceuticals & Health Services Competition Cases
Pharmaceutical companies, biotechnology firms, medical-device manufacturers, healthcare providers, investors and public authorities can consult the Commission’s Pharmaceuticals & Health Services Cases and Judgments page to follow antitrust investigations, cartel decisions, merger reviews and State aid cases involving medicines, pharmaceutical manufacturing, healthcare activities and social-care services.
Why this matters for businesses and healthcare authorities
Competition-policy developments in pharmaceuticals and health services can directly affect research, product launches, licensing, pricing, procurement, mergers and access to healthcare markets.
Businesses and public authorities should monitor:
For pharmaceutical companies, biotechnology firms, medical-device manufacturers, healthcare providers, investors and public purchasers, understanding competition policy is essential for managing legal risk and identifying new market opportunities.
Follow EU antitrust cases, merger reviews, State aid decisions and enforcement developments shaping pharmaceuticals, medical technologies and health services in Europe.
Competition-policy developments in pharmaceuticals and health services can directly affect research, product launches, licensing, pricing, procurement, mergers and access to healthcare markets.
Businesses and public authorities should monitor:
- antitrust investigations involving pharmaceutical companies;
- generic and biosimilar market-entry disputes;
- patent-settlement cases;
- mergers affecting medicines, devices and innovation pipelines;
- competition in healthcare procurement;
- pricing and reimbursement practices;
- access to medical data and technical interfaces;
- State aid for healthcare infrastructure and research;
- distribution and medicine-supply arrangements;
- Commission and national competition-authority decisions.
For pharmaceutical companies, biotechnology firms, medical-device manufacturers, healthcare providers, investors and public purchasers, understanding competition policy is essential for managing legal risk and identifying new market opportunities.
Follow EU antitrust cases, merger reviews, State aid decisions and enforcement developments shaping pharmaceuticals, medical technologies and health services in Europe.
